Explore the headlines set to surface at ESMO 2025.
ADCs make their move into early-stage disease
Drugs like Enhertu and Padcev, already headline-makers in metastatic disease, are now making waves in early-stage settings. DESTINY-Breast05, DESTINY-Breast11, and KEYNOTE-905 will hit presidential sessions, and will raise questions on safety in curable populations and how these developments align with de-escalation and ctDNA-guided strategies.
Pluvicto eyes expansion into mHSPC
With PSMAddition results, Pluvicto aims to move from mCRPC to hormone-sensitive prostate cancer (mHSPC). Attention will focus on patient selection for radioligand therapies (RLT) amid greater competition and a younger patient population, as well as the scalability of RLT to support this additional population.
IO plus BCG; a new SOC for NMIBC?
Checkpoint inhibitors moving earlier in non-muscle invasive bladder cancer (NMIBC) could help prevent recurrence and reduce the need for radical surgery. Results from two phase III trials are coming in BCG-naïve NIMBC: POTOMAC, toplined positive (though not OS-powered), and ALBAN, still unreported. Will ESMO give a clear green light – or leave the field with mixed signals?
ctDNA guiding adjuvant IO strategy in MIBC
IMvigor011 could redefine adjuvant decision-making in MIBC. While surgery ± neoadjuvant chemotherapy remains standard, relapse rates are high – yet IMvigor010 showed no benefit for adjuvant IO in all comers. IMvigor011 suggests a smarter path forward, with DFS and OS benefits when IO is reserved for ctDNA-positive, high-risk patients.
China’s oncology breakthroughs
Three China-only Phase III trials feature in ESMO’s presidential lineup, highlighting China’s growing influence on global oncology. With ivonescimab showing domestic results can translate internationally, these trials will be watched as a “first look” ahead of broader studies.
Our oncology team is ready to discuss how the latest oncology developments could shape strategy and decisions. Reach out and meet us at ESMO 2025.